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Abstract
Background: Facioscapulohumeral muscular dystrophy (FSHD) is an autosomal dominant neuromuscular disorder
associated with the partial deletion of integral numbers of 3.3 kb D4Z4 DNA repeats within the subtelomere of
chromosome 4q. A number of candidate FSHD genes, adenine nucleotide translocator 1 gene (ANT1), FSHD-related
gene 1 (FRG1), FRG2 and DUX4c, upstream of the D4Z4 array (FSHD locus), and double homeobox chromosome 4
(DUX4) within the repeat itself, are upregulated in some patients, thus suggesting an underlying perturbation of the
chromatin structure. Furthermore, a mouse model overexpressing FRG1 has been generated, displaying skeletal muscle
defects.
Results: In the context of myogenic differentiation, we compared the chromatin structure and tridimensional interaction
of the D4Z4 array and FRG1 gene promoter, and FRG1 expression, in control and FSHD cells. The FRG1 gene was
prematurely expressed during FSHD myoblast differentiation, thus suggesting that the number of D4Z4 repeats in the
array may affect the correct timing of FRG1 expression. Using chromosome conformation capture (3C) technology, we
revealed that the FRG1 promoter and D4Z4 array physically interacted. Furthermore, this chromatin structure
underwent dynamic changes during myogenic differentiation that led to the loosening of the FRG1/4q-D4Z4 array loop
in myotubes. The FRG1 promoter in both normal and FSHD myoblasts was characterized by H3K27 trimethylation and
Polycomb repressor complex binding, but these repression signs were replaced by H3K4 trimethylation during
differentiation. The D4Z4 sequences behaved similarly, with H3K27 trimethylation and Polycomb binding being lost upon
myogenic differentiation.
Conclusion: We propose a model in which the D4Z4 array may play a critical chromatin function as an orchestrator
of in cis chromatin loops, thus suggesting that this repeat may play a role in coordinating gene expression.
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Facioscapulohumeral muscular dystrophy (FSHD) is an
autosomal dominant disease with a prevalence of
1:20,000 [1] that is characterized by weakness and atro-
phy of the muscles of the face, upper arms and shoulder
girdle. The FSHD locus has been mapped by linkage anal-
ysis to the subtelomeric region of the long arm of chromo-
some 4 (4q35) [2,3]. The disorder is associated with the
deletion of an integral number of tandemly arrayed 3.3-
kb units (D4Z4) [4]. Each D4Z4 repeat contains two
homeoboxes within a single predicted open reading frame
(ORF), double homeobox chromosome 4 (DUX4). The
number of repeats varies from 11 to 110 in normal sub-
jects, but is consistently less than 11 in FSHD patients [5],
a contraction that is predominantly associated with a spe-
cific variant of chromosome 4 called 4qA [6-8]. Only a few
patients with phenotypic FSHD show normal-sized D4Z4
repeats on both chromosomes 4. It is interesting to note
that the D4Z4 repeats in patients with D4Z4 contractions
or phenotypic FSHD show reduced levels of DNA methyl-
ation. D4Z4 hypomethylation is more prominent and
present on both chromosomes 4 in patients with pheno-
typic FSHD, but it is restricted to the diseased chromo-
some in those with 4q-linked FSHD [9,10].
The region immediately proximal to the D4Z4 repeats
harbors a number of candidate genes. This FSHD locus
includes FSHD-related gene 1 (FRG1) [11], which
encodes a nucleolar protein involved in RNA biogenesis
[12]; TUBB4q, a member of the β-tubulin family; and
FRG2, a predicted transcript with no significant homology
to any known protein. The adenine nucleotide transporter
1 gene (ANT1), a gene involved in apoptosis, lies more
distally from the 4qter (5.8 Mb) [13].
In addition to the DUX4 ORF within each unit of the tan-
dem array, there is a DUX4-like sequence (named DUX4c)
near FRG2. Preliminary data suggest that DUX4c may be
expressed in FSHD samples [14], and it has been shown
that its ectopic overexpression interferes with myogenic
regulators and abolishes myoblast differentiation [15].
The expression of DUX4 RNA and protein has recently
been selectively detected in primary myoblasts from
FSHD patients, thus suggesting its involvement in FSHD
[14,16]. Furthermore, the overexpression of DUX4 in dif-
ferent cell lines induces cell toxicity and apoptosis
[14,17]. The overexpression of FRG2, FRG1, and ANT1
has been found in some muscles affected by FSHD [18-
20]. It has also been shown that a transcriptional repressor
complex binds D4Z4, and it is thought that D4Z4 dele-
tion would trigger gene overexpression as a result of the
lack of repression [18]; the overexpression of FRG1, but
not ANT1 and FRG2, in transgenic mice leads to a general
muscle dystrophy [21]. Furthermore, FRG1 overexpres-
sion in FSHD samples is not a uniform finding, [22,23]
and thus the contribution of the FRG1 gene to the FSHD
phenotype needs further validation. The transcriptional
alterations reported above in some of the genes of the
FSHD locus may be caused by a perturbation of the chro-
matin structure driven by the deletion of D4Z4 units [24].
This paper describes the crosstalking molecular events
that occur within the FSHD locus. We concentrated on
FRG1 because, although it is indicated as a candidate gene
for FSHD pathogenesis, the molecular link between D4Z4
deletion and FRG1 deregulation remains unclear. We
found that FRG1 is upregulated during myogenic differen-
tiation and that FSHD myoblasts show significantly pre-
mature FRG1 expression in the early stages of
differentiation. We investigated the chromatin features of
FRG1 at hierarchical levels during myogenic differentia-
tion in myoblasts derived from FSHD patients and nor-
mal individuals, and found that the FRG1 promoter
undergoes chromatin remodeling involving the loss of the
Polycomb repressor complex. Parallel analysis of D4Z4
repeats showed that the chromatin is marked by
H3K27me3 (which is reduced in FSHD contracted alleles)
and the Polycomb complex, and that both repressive
markers are lost in myotubes. We further demonstrated
that the physical interaction of the non-contiguous FRG1
and D4Z4 array, which is loosened in FSHD myoblasts, is
remodeled upon cell differentiation. These results provide
a connection between the deletion of D4Z4 repeats and
the misregulation of the FRG1 candidate gene in FSHD
cells.
Results
FRG1 expression is upregulated during the myogenic 
differentiation of human myoblasts
We investigated the mechanisms that regulate FRG1 gene
transcription during the myogenic differentiation of
human primary myoblasts. All experiments were per-
formed using three myoblast cell lines derived from
healthy donors, and four cell lines derived from FSHD
patients (see Additional file 1a).
We first monitored myotube formation by means of
immunostaining with sarcomeric myosin and MyoD anti-
bodies after 2, 4 and 8 days of myogenic differentiation
(Additional file 1b), and analyzed the expression of skel-
etal muscle-specific markers in myoblasts and myotubes
after 8 days of differentiation (reverse transcription
polymerase chain reaction (RT-PCR) analysis of myo-
genin, MyoD and myosin in Additional file 1c). The per-
centage formation was calculated as the number of 4',6-
diamidino-2-phenylindole (DAPI)-positive nuclei in
myotubes (positive cells) divided by the total number of
nuclei in the area, and the obtained fusion index ranged
from 60% to 90% (Additional file 1a).
The expression of sarcomeric myosin during myogenic
differentiation (days 0, 1, 4 and 8) was checked by meansPage 2 of 15
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indicated that both the control and FSHD muscle cells
were undergoing correct myogenic differentiation and
had comparable differentiation properties.
These experimental conditions were used to analyze FRG1
expression at transcriptional and protein levels by RT-PCR
and western blotting. FRG1 mRNA and protein expression
was higher in the myotubes than in the myoblasts (Figure
1a, b); these data were confirmed in all the available cell
lines (data not shown). RT-PCR analysis of a panel of
adult human tissue RNA showed that FRG1 expression
was not restricted to muscle cells (Figure 1c). FRG1 there-
fore seems to be subject to muscle-specific regulation, but
is not a classic muscle gene.
We then analyzed FRG1 myogenic regulation at the his-
tone code level using chromatin immunoprecipitation
(ChIP) experiments, and found that the H3K27 trimethyl-
ation (H3K27me3) repression marker (but not
H3K9me3) on the FRG1 promoter in myoblasts was
replaced by the H3K4me3 activation marker in myotubes
(Figure 1d part i). H3K4me3 was also present on the FRG1
promoter in other human non-muscle cells expressing
FRG1 [25], such as HeLa and lymphoblasts (Figure 1d part
ii). These findings suggest that the very low FRG1 mRNA
level observed in myoblasts is caused by active repression,
based at least on the trimethylation of H3K27, whereas
H3K4me3 is a hallmark of gene activation. The switch
between H3K27me3 and H3K4me3 was monitored in all
of the available myoblasts and myotubes, and found to be
statistically significant in both controls and patients (Fig-
ure 1e).
It has been previously shown that several muscle-specific
genes in myoblasts are silenced as a result of the promoter
recruitment of the histone H3K27 methyltransferase
(HKMT) Ezh2 via YY1, two key components of the Poly-
comb complex [26], and that changes in H3K27 and YY1
binding can be associated with DNA methylation [27].
Upon gene activation, YY1 and Ezh2 dissociate from their
target promoters, H3K27 becomes hypomethylated, and
MyoD and serum response factor (SRF) are recruited [26].
We analyzed the FRG1 promoter sequence using MatIn-
spector software (Genomatix, Munich, Germany) and
identified one CarG box (the DNA binding site of the YY1
protein) at position -371 from the transcriptional start site
(+1), and two flanking E-boxes (the DNA binding site of
the MyoD transcription factor) at positions -448 and -232
(Figure 1f part i). For these analyses, as the FRG1 genomic
region is duplicated in the human genome [11,28], we
designed primer pairs specifically aimed at the 4q FRG1
genomic copy and confirmed their selectivity by means of
a panel of human somatic cell monohybrids (Additional
file 2). We performed ChIP experiments on myoblasts and
myotubes using antibodies against H3K27me3, YY1, Ezh2
targeting the FRG1 YY1 regulatory region (FRG1 A) and
the proximal promoter (FRG1 B) as a control (Figure 1f
part i) (see Additional file 3 for the PCR primer pairs). In
myoblasts, YY1 and Ezh2 were detected on CarG box
(FRG1 A), and H3K27me3 widely marked the FRG1 pro-
moter (FRG1 A and FRG1 B) (Figure 1f part ii).
We also carried out a methylated DNA immunoprecipita-
tion (MeDIP) assay of the same FRG1 promoter regions
(FRG1 A and FRG1 B) to analyze the DNA methylation
status of the promoter, and mapped a region of DNA
methylation in correspondence with the YY1 binding site
(compare FRG1 A and FRG1 B in Figure 1f part ii). After 8
days of differentiation, Polycomb complex binding and
the H3K27me3 marker were lost (Figure 1f part ii); how-
ever, there was no change in the DNA methylation pattern
of the promoter, as has been previously reported in the
case of other muscle genes [29]. Additional file 4a shows
examples of the ChIP and MeDIP analyses of the FRG1
promoter.
These results indicate that FRG1 gene expression is regu-
lated during human myogenic differentiation, and that
the gene behaves in the same way as other muscle fiber-
specific genes [26].
The FRG1 gene is prematurely expressed at early stages of 
FSHD myoblast differentiation
The finding of FRG1 upregulation in muscle biopsies of
FSHD patients is controversial [16,18,21,23], and previ-
ous studies have failed to detect any significant difference
of FRG1 expression levels in FSHD myoblasts [22,23,30].
We therefore compared the pattern of FRG1 mRNA
expression during differentiation in FSHD and control
cells.
FRG1 expression was analyzed in three FSHD and three
control muscle biopsies by means of real time RT-PCR
using primer pairs that exclusively amplified the 4q FRG1
copy [11]. In agreement with previous studies, we
observed that FRG1 overexpression in muscle biopsies is
not a uniform finding; indeed, only one FSHD sample
showed FRG1 upregulation (Figure 2a). As FRG1 showed
muscle-specific upregulation (Figure 1a), we performed
this analysis in primary myoblasts derived from the same
muscle biopsies and during their myogenic differentiation
of (Figure 2b). No FRG1 overexpression was detected in
FSHD myoblasts, as these samples did not show any sta-
tistical significant difference compared to control cells.
Indeed, two control samples showed a basal level of FRG1
expression higher than FSHD. Moreover, all the samples
showed FRG1 upregulation during myoblasts differentia-
tion (from day 0 to day 8). In particular, the comparison
of FSHD and control cells at each timepoint of differenti-
ation for the increase of FRG1 mRNA level (in relation to
the corresponding values at day 0) showed statistically sig-Page 3 of 15
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Facioscapulohumeral muscular dystrophy-related gene 1 (FRG1) upregulation during myogenic differentiation is marked by a switch between H3K27me3 n  Polycomb factors with H3K4me3 on its promoterigure 1
Facioscapulohumeral muscular dystrophy-related gene 1 (FRG1) upregulation during myogenic differentiation 
is marked by a switch between H3K27me3 and Polycomb factors with H3K4me3 on its promoter. FRG1 mRNA 
and protein were detected by reverse transcription polymerase chain reaction (RT-PCR) (a) and western blotting (b) in 
myoblasts and myotubes (8 days of differentiation); 18S rRNA and b tubulin were used as controls. (c) Total RNA from adult 
tissues was tested for FRG1 expression by means of RT-PCR; 18S rRNA was used as a control. Histograms in A and C repre-
sent FRG1 expression over 18S rRNA. (d) Chromatin immunoprecipitation (ChIP) assays of (i) myoblasts and myotubes, and 
(ii) HeLa and lymphoblasts, using antibodies against H3K4me3 (K4), H3K9me3 (K9) and H3K27me3 (K27). Input DNA (+) rep-
resents total chromatin, and IgG the immunoprecipitation by normal rabbit IgG. The amplified FRG1 promoter subregion cor-
responds to FRG1 A in (f)(i). The G6PD promoter was amplified as a negative H3K27me3 control. (e) ChIP analyses of control 
(CN) and facioscapulohumeral muscular dystrophy (FSHD) myoblasts and myotubes, indicating the standard error of the mean. 
A two-tailed t test was used for statistical analysis; the asterisks indicate the statistically significant differences at α = 0.05. CN-
K27me3/CN-K4me3 in myoblasts: P = 0.0167, n = 3; FSHD-K27me3/FSHD-K4me3 in myoblasts: P = 0.0157, n = 4; CN-
K27me3/CN-K4me3 in myotubes: P = 0.0006, n = 3; FSHD-K27me3/FSHD-K4me3 in myotubes: P < 0.0001, n = 4. The RT-
PCR primer pairs were 4q specific [11], and are shown in Additional file 3; the anti-FRG1P antibody is specific for a 4q FRG1 
peptide [21]. (f)(i) A schema of the FRG1 promoter showing the position of one CarG box responsive element (in red) and 
two E-boxes (in green) in relation to the ATG and transcription start site (+1), and the PvuII site. The arrowheads indicate the 
primer positions for the FRG1 A and FRG1 B PCRs. (ii) ChIP and methylated DNA immunoprecipitation (MeDIP) experiments 
on myoblasts and myotubes using the anti-H3K27me3 (K27me3), anti-Ezh2, anti-YY1, and anti-5-methyl cytidine (5meCy) anti-
bodies. All PCR experiments were performed in a linear range of amplification, and band intensities were measured using a 
Typhoon 9200 phosphoscanner and Image Quant analysis software; after subtracting the signals derived from IgG immunopre-
cipitation, the results were expressed as percentages of input DNA.
BMC Biology 2009, 7:41 http://www.biomedcentral.com/1741-7007/7/41nificant results only for FSHD samples at day 1. We then
derived the overall kinetics of FRG1 expression during
myogenic differentiation of FSHD and control cells as
median values of FRG1 expression at each point of differ-
entiation (days 0, 1, 4 and 8), after the subtraction of the
value at day 0 (Figure 2c). This analysis confirmed that in
FSHD samples the FRG1 transcription at day 1 is signifi-
cantly upregulated with respect to controls (Figure 2b, c).
We verified that this was not due to a higher rate of differ-
entiation because the myosin levels monitored at the
same time were similar in the FSHD and control samples
(Additional file 1d). In conclusion, these data suggest that
the difference between patients and controls for the FRG1
expression states in the kinetics of transcription during
myogenic differentiation.
Chromatin structure and the nuclear topology of D4Z4 
array in FSHD and control muscle cells
The same chromatin analyses as those described above
were used to examine the D4Z4 sequences. The MatIn-
spector software revealed two CarG boxes in specific sub-
regions of the repeat, which are indicated as D4Z4
Anticipated facioscapulohumeral muscular dystrophy-related gene 1 (FRG1) expression during facioscapulohumeral muscular dystrophy (FSHD) myoblast differentiationFigure 2
Anticipated facioscapulohumeral muscular dystrophy-related gene 1 (FRG1) expression during facioscapulo-
humeral muscular dystrophy (FSHD) myoblast differentiation. (a) FRG1 expression in three healthy (CN) and three 
FSHD muscle biopsies (FSHD) as revealed by means of a quantitative reverse transcription polymerase chain reaction (qRT-
PCR) analysis relative to glyceraldehyde 3-phosphate dehydrogenase (GAPDH) expression. (see Additional file 3 for primers), 
indicating the standard deviation of the mean. A two-tailed t test was used for statistical analysis; the asterisk indicates the sta-
tistical significant difference between FSHD1 and CN3 (the control with the highest level of FRG1 expression): a = 0.05, P = 
0.023. (b) FRG1 expression during myogenic differentiation in healthy (CN) and FSHD (FSHD) samples, expressed as fold of 
GAPDH expression, indicating the standard deviation of the mean. A two-tailed t test was used for statistical analysis; asterisks 
indicate the statistical significant differences between: FSHD1 day 1/FSHD1 day 0, α = 0.05, P = 0.0031; FSHD2 day 1/FSHD2 
day 0, α = 0.05, P = 0.0035; FSHD3 day 1/FSHD3 day 0, α = 0.05, P = 0.0036; FSHD4 day 1/FSHD4 day 0, α = 0.05, P = 0.0033. 
(c) Kinetics of FRG1 expression during myogenic differentiation in control and FSHD cell lines; the values were determined as 
median of FRG1 expression at each step of differentiation (days 0, 1, 4 and 8) after subtracting the median value at day 0. The 
standard error of the mean was indicated. A two-tailed t test was used for statistical analysis; the asterisks indicate the statisti-
cally significant differences at α = 0.05; controls, n = 3; FSHD, n = 4; CN day 1/FSHD day 1, P = 0.0001. These results were 
derived from at least three independent RNA extractions for each human cell line.Page 5 of 15
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ure 3a part i. A YY1 binding site has been previously
described in the D4Z4 repeat [18] and, in our schema, it
coincides with the CarG box within the DBE1 region (Fig-
ure 3a part i).
We then performed ChIP experiments on three 3.3 kb
subregions of the D4Z4 unit (Lsau, DBE1 and DBE2) (Fig-
ure 3a part i). The results obtained for DBE1 and Lsau are
summarized in Figure 3a part ii; the results for DBE2 (not
shown) were the same as those obtained for DBE1. In
myoblasts, the YY1 and Ezh2 Polycomb factors and
H3K27me3 were associated with the CarG box-containing
sequences (DBE1 and DBE2), but not with Lsau; in myo-
tubes, the Polycomb factors were no longer present in any
of the regions (Figure 3a part ii). Furthermore, as with the
FRG1 promoter (Figure 1f part ii), only YY1 binding sites
were methylated, regardless of the presence of YY1 bind-
ing (before and after myogenic differentiation). Examples
of the ChIP analyses of the D4Z4 subregions are shown in
Figure 3a part iii.
To test the hypothesis that the premature activation of the
FRG1 gene during the differentiation of FSHD cells may
have been due to a weaker repression mechanism medi-
ated by the contracted D4Z4 allele, we compared H3K27
trimethylation levels in the D4Z4 repeats in control and
FSHD myoblasts before and after myogenic differentia-
tion. As shown in Figure 3b, the ChIP experiments did not
detect any appreciable differences in the H3K27 trimeth-
ylation between the healthy controls and FSHD cells.
Because of the extensive duplication of D4Z4 sequences in
the human genome [25,31], the PCR primers used were
not 4q specific (see Additional file 2), and so the results
refer to all of the D4Z4 sequences in the nucleus. It is
therefore possible that a difference in D4Z4 H3K27 meth-
ylation between normal and FSHD cells (attributable to
the fewer D4Z4 repeats in the contracted allele) may lead
to a variation that is too small to be detected by the ChIP
assay. However, ChIP experiments using monochromo-
somal cell hybrids retaining chromosome 4 indicate the
presence of H3K27 trimethylation and YY1 on DBE
sequences (D. Cabianca and D. Gabellini, personal com-
munication, Division of Regenerative Medicine San Raf-
faele Scientific Institute DIBIT, Milan, Italy); moreover,
MeDIP DNA methylation experiments using monochro-
mosomal cell hybrids retaining chromosomes 4, 10 and
acrocentrics show that only the DBE sequences on chro-
mosome 4 and 10 are methylated (Additional file 4b).
Furthermore, myogenic differentiation triggered the chro-
matin remodeling of the D4Z4 sequences as a whole and
induced a significant reduction in the Polycomb signals
(H3K27me3, YY1 and Ezh2) (Figure 3a part iii). Taken
together these results suggest that 4q D4Z4 repeats may be
Chromatin structure of D4Z4 units in human myoblastsFigure 3
Chromatin structure of D4Z4 units in human myob-
lasts. (a)(i) A simplified schema of the D4Z4 unit showing 
the position of two CarG box responsive elements 
(sequences in red). The arrowheads indicate the primer posi-
tions for the Lsau, D4Z4 binding element (DBE)1 and DBE2 
subregions; the PvuII restriction site positions are indicated. 
(ii) Chromatin immunoprecipitation (ChIP) and methylated 
DNA immunoprecipitation (MeDIP) experiments on myob-
lasts and myotubes using anti-H3K27me3 (K27me3), Ezh2, 
YY1, and 5-methyl cytidine (5meCy) antibodies (iii) Examples 
of ChIP experiments on the Lsau and DBE1 subregions in 
myoblasts and myotubes. (b) H3K27 trimethylation of D4Z4 
sequences before (day 0) and after (day 8) myogenic differen-
tiation in healthy control (CN) and facioscapulohumeral mus-
cular dystrophy (FSHD) cell lines, as revealed by ChIP 
experiments on the DBE1 subregion using anti-H3K27me3 
antibody (red), indicating the standard error of the mean. A 
two-tailed t test was used for statistical analysis; the asterisks 
indicate the statistically significant differences at α = 0.05. 
CN-day 0/CN-day 8: P = 0.0172, n = 3; FSHD-day 0/FSHD-
day 8: P = 0.0003, n = 4. All of the polymerase chain reaction 
(PCR) experiments were performed in a linear range of 
amplification, and band intensities were measured using a 
Typhoon 9200 phosphoscanner and Image Quant analysis 
software; after subtracting the signals derived from immuno-
precipitation with IgG antibody, the results were expressed 
as percentages of input DNA. The primer pairs are shown in 
Additional file 3.Page 6 of 15
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H3K27me3, YY1 and Ezh2 antibodies. However, as the
primer pairs used amplify DBE sequences from many
chromosomes (see Additional file 2), the obtained ChIP
signals might also derive from genomic localizations of
D4Z4 other than 4q. Since ChIP experiments do not pro-
vide direct evidence on the chromatin structure of the 4q
D4Z4 array in myoblasts or on the presence of differences
between healthy and FSHD cells, we used 3D fluorescence
in situ hybridization (3D-FISH) as a complementary strat-
egy.
To identify the 4q subtelomere, we used a cocktail of three
DNA probes: two were bacterial artificial chromosomes
(BACs) of the FSHD locus, one containing D4Z4 repeats
(green in Figure 4 part i) and one not overlapping located
130 kb upstream of the D4Z4 array (red in Figure 4 parts
i and ii) (see Methods for details), and the third was a
painting for chromosome 4 territory (blue in Figure 4
parts i and ii). We followed their colocalization in order
to analyze the nuclear architecture of the FSHD locus
(arrows in Figure 4) and distinguish the two 4q alleles in
the nucleus; one 4q allele in almost all FSHD nuclei
shows a weaker hybridization signal [32], and this was
considered the bona fide contracted allele (Figure 4 part ii,
arrowheads). We then investigated the nuclear position of
the FSHD locus identified by the three probes (relative to
dense H3K27me3 signals) in FSHD and control myoblast
nuclei.
The nuclei were stained with an H3K27me3-specific anti-
body (red in Figure 4 parts iii, iv, v, vi and vii), and 30
were scored in both the healthy and FSHD myoblasts.
Colocalization with anti-H3K27me3 immunofluores-
cence (yellow in Figure 4 part iii) was observed in 72.4%
of the 4q alleles in the healthy cells (examples of negative
and positive H3K27me3 colocalization are shown in Fig-
ure 4 parts iv and v). In particular, the majority of the non-
4q D4Z4 signals (mainly attributed to the short arms of
acrocentric chromosomes) [25,31] were concentrated in
nucleolar subdomains that are known to be H3K27me3
negative [33]. In contrast, the FSHD nuclei showed colo-
calization with H3K27me3 signals in only 38.6% of the
4q alleles (yellow in Figure 4 parts vi and vii) (P =
0.0013). The H3K27me3 colocalized signals were attrib-
uted mainly to the wild-type allele identified by the larger
Nuclear topology of D4Z4 units in control and FSHD myoblastsFigure 4
Nuclear topology of D4Z4 units in control and FSHD myoblasts. 4q subtelomere architecture in 1.4 μm midprojec-
tions of 3D-preserved interphase nuclei from healthy (i, iii, iv and v) and FSHD myoblasts (ii, vi and vii) immunofluorescence in 
situ hybridization (immuno-FISH) using anti-H3K27me3 antibody (scale bar = 5 μm). The chromosome 4q territories are 
shown in blue, the bacterial artificial chromosome (BAC) upstream of the FRG1 gene in red, and the BAC containing a D4Z4 
array in green. The arrows highlight the 4q subtelomeres identified by the cohybridization of both BACs and the chromosome 
4 painting. The arrowhead in (ii) identifies a 4q subtelomere showing reduced hybridization with the green BAC and probably 
corresponding to the contracted D4Z4 allele. (iii) and (vi) The same nuclei as those respectively shown in (i) and (ii) were 
immunostained with anti-H3K27me3 antibody (red); the green spots correspond to hybridization with the D4Z4-containing 
BAC; the arrows and arrowhead identify the 4q alleles. (iv) and (v) Representative confocal sections of a nucleus from healthy 
myoblasts consisting of 4q D4Z4 alleles (green) that were negative ((iv), only green) or positive ((v), green and yellow) for 
colocalization with anti-H3K27me3 immunofluorescence (red). (vii) A 3 × enlargement of the confocal section in (vi) showing a 
nucleus from FSHD myoblast consisting of 4q D4Z4 alleles (green) that were negative (arrowhead, only green) or positive 
(arrow, green and yellow) for colocalization with anti-H3K27me3 immunofluorescence (red).Page 7 of 15
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tion in the colocalization of H3K27me3 signals and con-
tracted alleles may have been due to the fact that the
FSHD alleles give smaller FISH spots, thus preventing us
from concluding that the contracted alleles were H3K27
hypomethylated; nevertheless, the different size of the
spot undoubtedly reflects a different concentration of
H3K27me3 in that subregion of the FSHD nucleus. This
experiment, which allows the direct visualization of the
tridimensional chromatin structure in vivo, revealed that
the majority of D4Z4 sequences modified by H3K27me3
belonged to the array on chromosome 4; moreover, we
detected significant differences between the patients and
controls that cannot be detected by high resolution PCR-
based techniques such as ChIP. Paradoxically, when work-
ing with highly repeated DNA sequences clustered on sev-
eral chromosomes, it is essential to use an approach that
distinguishes the genomic derivations of the signals in
order to be able to monitor differences attributable to a
specific chromosomal locus (that is to say, the D4Z4 array
on chromosome 4q) even with a low-resolution tech-
nique.
A specific 4q D4Z4-mediated chromatin loop involving the 
FRG1 promoter is dynamically regulated during human 
myoblast differentiation
It has been recently demonstrated that the formation of
higher order structures is a powerful mechanism coordi-
nating the expression of distant loci in the genome [34].
In order to verify whether the D4Z4 array and FRG1 gene
physically interact in human myoblasts and myotubes, we
investigated this association using chromosome confor-
mation capture (3C) technology [35] (see Additional file
5 for the detailed protocol), and scanned 90 kb spanning
the FSHD locus using primers flanking PvuII restriction
sites (Figure 5a). The PvuII restriction enzyme was selected
because it cuts in proximity to CarG sequences on both
FRG1 and the D4Z4 unit (see Figure 1f part i and Figure
3a part i).
A number of controls are essential for the correct interpre-
tation of 3C data [36]. We confirmed that all of the 3C
primers amplified artificial 3C products in vitro (see Addi-
tional file 6a and Additional file 5 for details), and did not
amplify undigested and ligated, or digested but not
ligated, chromatin (data not shown). Furthermore, all of
the 3C products derived from crosslinked and BAC tem-
plates were sequenced and corresponded to the expected
sequences (not shown). We selected two baits in the prox-
imity of the two PvuII restriction sites in the D4Z4 unit:
one (D1) detected the PvuII-D4Z4 fragment containing
the CarG sequences and discriminated D4Z4 repeats and
the unique copy located between the FRG1 and FRG2
genes (DUX4c); the second (D2) detected the remaining
portion of the repeat and also a DUX4c PvuII fragment
(see the schema in Figure 5a). We also designed two baits
specific for DUX4c PvuII fragments (C1 and C2). A total of
16 preys (F series) were positioned flanking the PvuII sites
in the FRG1 genomic region (see schema in Figure 5a),
and an additional 5 proximal to the D1 baits (1 to 5 in Fig-
ure 5a) were used to confirm that interactions between D1
and the nearby PvuII restriction fragments were quantita-
tively detected (an index validating the quality of a 3C
assay). We measured the crosslinking frequencies between
these baits and the various PvuII sites throughout the
FSHD locus. D1 (Figure 5b) and D2 (not shown) showed
one intrachromosomal loop between the D4Z4 array and
the FRG1 promoter (F7) in human myoblasts, and two
additional interactions with the TUBB4q gene (F16 and
F18). Interestingly, the D4Z4/FRG1 promoter interaction
was specific to the PvuII fragment-containing CarG box
(red rectangle in Figure 5a). Additional file 6a shows an
example of these findings.
To test the correlation between the derived chromatin
structure and the transcriptional potential of the FRG1
promoter, we performed similar 3C analyses after myo-
genic differentiation. In striking contrast to the presence
of long-range associations between D4Z4, FRG1 and the
TUBB4q in undifferentiated myoblasts, myogenic differ-
entiation led to an almost complete loss of the interaction
with the FRG1 promoter (P < 0.05 in all cases, see Addi-
tional file 6b, c for examples), and the locus acquired a
more relaxed conformation; conversely, the interaction
between D4Z4 and TUBB4q did not seem to be affected by
the differentiation process (Figure 5b). The same 3C anal-
ysis of a monochromosomal cell hybrid retaining human
chromosome 4 gave similar results (Additional file 7b),
thus demonstrating that the loops were formed between
sequence elements localized on chromosome 4.
To investigate whether DUX4c could also mediate similar
interactions, we set up a 3C analysis using the C1 and C2
baits described above. The use of C1 revealed an interac-
tion between the FRG1 promoter and the DUX4c frag-
ment that did not change during differentiation
(Additional file 7c), whereas no interactions were revealed
by C2 (not shown). Notably, the relative crosslinking fre-
quency was one order of magnitude lower with the
DUX4c bait than with the D4Z4 baits (compare F7-D1
with F7-C1 in Figure 5b, and Additional file 7c).
As the expression of the FRG1 gene is misregulated in
FSHD cells (Figure 2), we investigated whether the D4Z4
contraction affects loop formation by making the same
3C analysis of FSHD myoblasts and myotubes, but we did
not find any significant differences from controls (Figure
5b). However, reasoning that the wild-type allele may
mask a possible small reduction in the frequency of the
interactions, we used a 3C quantitative PCR (3C-qPCR)
assay in order to determine the crosslinking frequencies of
the F7-D1 interaction more accurately [37]. We designedPage 8 of 15
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the hybrid fragment generated by 3C, and normalized the
3C-qPCR results following the same procedures as those
used for the other 3C-PCRs (that is to say, normalization
by digestion, ligation and crosslinking efficiency). This
time, there was a slight but statistical significant reduction
in the interaction frequency of the FSHD myoblasts (Fig-
ure 5c). However, it is possible that a difference in the
D4Z4-FRG1 interaction between normal and FSHD cells
(attributable to the fewer D4Z4 repeats in the contracted
allele) may lead to a variation that is too small to be
detected by the 3C assay. These findings suggest that the
FSHD locus in muscle cells is structured into at least three
intrachromosomal loops: two steady loops connecting
D4Z4-TUBB4q, and one dynamic loop between D4Z4 and
the FRG1 promoter that is relaxed during myogenic differ-
entiation. This indicates that the higher order structure of
these elements undergoes dynamic remodeling, which
probably correlates with the disappearance of the Poly-
comb complex from both the FRG1 promoter and the
D4Z4 array, and is concomitant with the upregulation of
gene expression. Moreover, the ability to form loops
between the FRG1 promoter and the D4Z4 array seems to
be less efficient in FSHD myoblasts than in controls.
Discussion
Facioscapulohumeral dystrophy is considered an epige-
netic disorder [24]. Abnormalities in the expression of
candidate genes such as ANT1, FRG1 and FRG2, and in the
transcription of the D4Z4 repeat, have been reported in
FSHD patients [24], but the chromatin features of the
FSHD locus have not been studied in detail.
We found that the upregulation of FRG1 in FSHD patients
is a gain of function mechanism that could explain the
autosomal dominant inheritance of the disease, and that
Higher order structure of the facioscapulohumeral muscular dystrophy (FSHD) locusFi ure 5
Higher order structure of the facioscapulohumeral muscular dystrophy (FSHD) locus. (a) Diagram of the genomic 
region analyzed in the chromosome conformation capture (3C) experiments, indicating the PvuII restriction sites (thin vertical 
lines); the arrowheads indicate the primer positions, the F series in FSHD-related gene 1(FRG1), the C series in DUX4c, the D 
series in the D4Z4 repeats; the numbers from 1 to 5 indicate the restriction sites near the D1 bait used as positive controls. 
The red rectangles show the locations of CarG boxes. (b) The Y axis represents the crosslinking frequency expressed as the 
ratio of polymerase chain reaction (PCR) performed on 3C samples relative to bacterial artificial chromosome (BAC) controls 
between the fixed PvuII fragment D1 (D4Z4 repeats) and the rest of the FSHD locus after the correction for digestion and liga-
tion. The calculation of the relative crosslinking frequency between two given fragments, performed as described previously 
[43], allows a direct comparison between the different cell types used in the 3C assay by correcting for possible variants. All 
data points were generated from an average of three independent experiments. The standard error of the mean is indicated. 
One-way analysis of variance (ANOVA) was applied for statistical analysis; control myoblasts: α = 0.05, P = 1.81*10-12; control 
myotubes: α = 0.05, P = 3.14*10-6. To compare myoblasts and myotubes, two-way ANOVA was applied for statistical analysis: 
α = 0.05, P = 0.0073. (c) Frequency of interaction between the FRG1 promoter and D4Z4 sequences in FSHD and control 
myoblasts, indicating the standard error of the mean. Quantitative (q)PCR was performed on 3C templates using a TaqMan 
probe complementary to the FRG1 promoter portion of the PCR product obtained using F7 and D1 primers. The results are 
normalized to digestion, ligation and crosslinking efficiency, as described in Additional file 5. A two-tailed t test was used for 
statistical analysis; the asterisks indicate the statistically significant differences at α = 0.05. Controls, n = 3; FSHD, n = 4; P = 
0.021. The primers are shown in the detailed 3C protocol section of Additional file 5.Page 9 of 15
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the remodeling of the locus. FRG1P is a nuclear protein
that is thought to be involved in RNA processing [12,38].
Slight differences in the cell levels of regulatory proteins
such as FRG1P may affect a number of factors and have
multiple effects on cell physiology. For instance, the alter-
native splicing of muscle-specific genes is abnormally reg-
ulated in mice overexpressing FRG1 and showing an
FSHD phenotype [21], and so inappropriate regulation of
FRG1 during the early phases of muscle differentiation
may have serious effects on the formation of muscle fiber.
We suggest that FRG1 misregulation in a specific window
of muscle differentiation may contribute to FSHD,
although it cannot be considered the only molecular
defect causing the FSHD phenotype: for example, the tran-
scription of DUX4 recently observed in FSHD myoblasts
[14,16] may contribute to the manifestation of FSHD.
In order to investigate the molecular basis of the FRG1
transcriptional alteration, we made a detailed analysis of
the chromatin structure of two DNA regions residing in
the FSHD locus in a human model of myogenic differen-
tiation: the candidate gene FRG1 and the D4Z4 array, to
which the genetic mutation underlying the disease has
been mapped. These two DNA regions were studied at dif-
ferent levels of the epigenome, from DNA methylation
and histone code modifications to higher order structures.
In this regard, it is important to point out the intrinsic lim-
itation of molecularly analyzing repetitive DNA elements,
and so we used the complementary approaches of ChIP
and 3D-FISH analysis to gain insights into the chromatin
structure of D4Z4.
The analyses showed that the FSHD locus undergoes chro-
matin remodeling during myogenic differentiation. In
normal myoblasts, the FRG1 gene is repressed and its pro-
moter physically interacts with the D4Z4 array; upon dif-
ferentiation, the Polycomb complex dissociates from the
FRG1 promoter and the FRG1 gene is expressed. Like the
FRG1 promoter, D4Z4 chromatin also shows the presence
of the Polycomb complex and H3K27me3 in myoblasts,
and their loss in myotubes; moreover, D4Z4 and the
FRG1 promoter physically interact in myoblasts, whereas
this chromatin loop is relaxed upon myogenic differenti-
ation.
These data support the hypothesis that the 4q D4Z4 array
may have a regulatory effect on FRG1 expression, which
we suggest is due to their physical association in the
nucleus. It has recently been demonstrated that Polycomb
occupancy can repress transcription by maintaining a
series of long-range chromatin interactions that are lost
when mammalian cells differentiate [39], and so it would
be interesting to investigate directly the involvement of
the Polycomb repressor complex as a mediator of the
FRG1-D4Z4 chromatin loop in myoblasts.
Chromatin characterization of FRG1 and the D4Z4 array
in FSHD myoblasts revealed a reduction in H3K27me3 on
the contracted D4Z4 allele, and a kinetic analysis of Poly-
comb dissociation during differentiation that was very
similar to that observed in the control cells. The reduction
in H3K27me3 may be due to the decrease in the number
of D4Z4 units or to hypomethylation of the residual
repeats. Furthermore, the early expression of FRG1 in dif-
ferentiating FSHD myoblasts may indicate that muscle
cells, like their non-muscle counterparts, require the
recruitment of additional factors in order to activate FRG1
expression.
In our cell system, the regulation of FRG1 expression
therefore seems to be preferentially conditioned by the
chromatin structure of the region (that is to say, the
strength of the loop between the FRG1 promoter and the
D4Z4 array related to its chromatin structure). We found
a slight reduction in the frequency of loop formation
between the D4Z4 array and the FRG1 promoter in FSHD
myoblasts in comparison with control cells. D4Z4 con-
traction in FSHD cells may qualitatively alter the repres-
sive effect of this chromatin loop affecting the correct
timing of FRG1 expression. It is possible that relaxed loop-
ing in the presence of protein factors that may induce fur-
ther changes in chromatin conformation and/or more
efficient transcription allows the expression of the FRG1
gene. Nonetheless, the observed reduction in the fre-
quency of loop formation between the D4Z4 array and
the FRG1 promoter in FSHD myoblasts is too small to cer-
tainly infer its involvement in the misregulation of FRG1
gene expression, and thus further experiments are
required to link macrosatellite contraction and gene
expression.
Pirozhokova et al. [40] published a 3C analysis of the
FSHD locus and described the formation of loops
between DUX4c and the FRG1 promoter. We detected the
same loop in myoblasts, although the frequency of the
interaction was one order of magnitude lower than that of
the loop between FRG1 and D4Z4 sequences. The same
authors also found a second loop between a telomeric ele-
ment downstream of the D4Z4 array (the 4qA/B marker)
and the FRG1 promoter only in FSHD myoblasts, and sug-
gested that this element may enhance the transcription of
the gene [40]. As we did not detect FRG1 up regulation in
FSHD myoblasts, we suggest that the interaction with the
4qA/B marker have the proposed effect of transcription
enhancement on FRG1 expression only when myogenic
differentiation is triggered. Our data, together with data of
Petrov et al. and Pirozhokova et al. indicate that the tridi-
mensional structure of the FSHD region is functional for
the expression of the FRG1 gene, and probably more than
one sequence elements (for example, D4Z4, DUX4c, MAR
region) could contribute to the fine regulation of gene
expression [40,41].Page 10 of 15
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FSHD in the absence of D4Z4 contraction, as in the case
of phenotypic FSHD in which a wild-type 4q D4Z4 array
is strongly hypomethylated [9,10]. In this case, D4Z4
hypomethylation may impair the Polycomb recruitment
that leads to a reduction in H3K27 trimethylation, the
same molecular defect that we observed in contracted 4q
alleles.
Conclusion
The results of this study provide the first demonstration of
a mechanistic link between the D4Z4 array and the tran-
scriptional regulation of muscle-specific FRG1 via intrac-
hromosomal looping. This finding may predict a broader
role of the D4Z4 array in coordinating regulatory interac-
tions between non-contiguous elements in the genome.
The identification of such in cis or in trans interactions
may untangle the intricate cascade of events underlying
the manifestation of FSHD and may suggest that this
human disorder is an example of the structural modifica-
tion of the epigenome.
Methods
Cell cultures, immunofluorescence
Human primary myoblasts from healthy donors and
FSHD patients were obtained from the Telethon BioBank,
(Neuromuscular Diseases and Neuroimmunology Unit,
Muscle Cell Biology Laboratory, C. Besta Neurological
Institute). The cell lines were cultured in Dulbecco's mod-
ified Eagle medium (DMEM) supplemented with 20%
fetal bovine serum (FBS), insulin 10 mg/ml, human
fibroblast growth factor (hFGF) 25 ng/ml, human epider-
mal growth factor (hEGF) 10 ng/ml (proliferating
medium), and then induced to differentiate by means of
DMEM supplemented with 2% horse serum (differentiat-
ing medium). All of the patients satisfied the accepted
clinical criteria for FSHD. They had undergone DNA diag-
nosis and were identified as carriers of small (<38 kb, <11
repeats) 4q35-located D4Z4 repeat arrays, as determined
by p13E-11 hybridization to EcoRI-digested and EcoRI/
BlnI-digested genomic DNA. The details of the cell lines
are shown in Additional file 2. The HeLa and human lym-
phoblasts were cultured in DMEM and RPMI supple-
mented with 10% FBS, whereas the monochromosomal
somatic cell hybrids retaining human chromosome 4, 10,
15 and 22 (a gift of Professor M. Rocchi, Department of
Genetics and Microbiology, University of Bari, Italy) were
cultured in DMEM supplemented with 10% FBS. Cell
immunofluorescence was performed using the antibodies
MF20 1:3 (DSHB, University of Iowa, Iowa City, Iowa)
and anti-MyoD 1:100 (Dako, Dako Italia, Milan, Italy).
Total RNA extraction, RT-PCR and quantitative RT-PCR 
analysis
Total RNA was isolated from the cells using the RNeasy
Mini Kit (Qiagen, Milan, Italy), and the purified RNA was
treated with RNase-free DNase (Qiagen, Milan, Italy) to
remove any residual DNA.
Quantitative RT-PCR (qRT-PCR) analysis was performed
on an iQ5 real time PCR detection system (BioRad, Seg-
rate, Italy) using the iScript two-step RT-PCR Kit with
SYBR Green (BioRad, Segrate, Italy). The relative expres-
sion of the investigated genes was quantified after normal-
ization against β2 microglobulin, the 18S subunit of
ribosomal RNA and glyceraldehyde 3-phosphate dehy-
drogenase (GAPDH). For FRG1 and GAPDH real time RT-
PCR correlation coefficient for the amplification and PCR
efficiency were respectively R2 = 0.963 and R2 = 0.990, and
99.4% and 99.8%.
The primer pairs used for the real time amplifications are
shown in Additional file 3.
Protein isolation and western blotting
Total proteins were extracted using radioimmunoprecipi-
tation assay (RIPA) buffer and the western blot analysis
was carried out using standard techniques and the anti-
bodies anti-histone H3 (AbCam, Cambrige, UK) and
FRGIP (kindly provided by D. Gabellini, Division of
Regenerative Medicine San Raffaele Scientific Institute
DIBIT, Milan, Italy); polyclonal anti-β tubulin (Sigma,
Milan, Italy) was used as standard.
ChIP and MeDIP assays
ChIP was performed using 5 μg of normal rabbit IgG or
antibodies against Ezh2 (Zymed, South San Francisco,
California, US), and YY1 (Santa Cruz Biotechnology, Hei-
delberg, Germany), or antibodies against trimethylated
H3K4 (Upstate Biotech, Millipore, Milan, Italy), trimeth-
ylated H3K9 (Upstate Biotech, Millipore, Milan, Italy),
and trimethylated H3K27 (Upstate Biotech, Millipore,
Milan, Italy).
For the MeDIP assay, 5 μg of sonicated genomic DNA
(size: 200 to 600 bp) were immunoprecipitated with 5 vg
of antibody against 5-methyl cytidine (Diagenode
Biosence, Milan, Italy), and the immunoprecipitates were
collected for 3 h at 4°C with constant agitation using 10
μl tRNA (20 mg/ml), 20 μl salmon sperm DNA (10 mg/
ml) and 20 μl protein A-agarose beads added to the 1 ml
samples.
Cell fixation and immuno-FISH pretreatment
Healthy and FSHD myoblast cell lines were grown on
cover slips for 12 to 24 h, and the cells were fixed in 4%
paraformaldehyde (PFA) in 1 × phosphate buffered saline
(PBS) for 10 min and permeabilized with 0.5% Triton-
X100 (15 min). The cover slips were incubated for 1 h
with rabbit anti-H3 K27 trimethylated antibody (Milli-
pore, Milan, Italy) and biotinylated anti-rabbit antibod-
ies, and subsequently with 1% PFA/1 × PBS (10 min), 0.1Page 11 of 15
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erol/1 × PBS (at least 1 h). Finally, after repeated freeze/
thawing in liquid nitrogen, the cells were treated with
pepsin solution (2.5 mg/ml pepsin in 0.01 N HCL at
37°C) for 5 min, and the cover slips were stored at 4°C in
50% formamide/2 × saline-sodium citrate (SSC).
DNA probe labeling, hybridization and detection
The chromosome 4 painting probe was labeled by means
of degenerated oligonucleotide primed (DOP)-PCR in the
presence of tetramethyl-6-carboxyrhodamine-deoxyurid-
ine triphosphate (TAMRA-dUTP). The BAC clone RP11-
463J17 was labeled with Texas Red-dUTP, and the BAC
containing D4Z4 repeats (derived from a human genomic
library screening) (B. Bodega, unpublished results), was
labeled with digoxigenin-dUTP by nick-end translation.
Between 100 ng and 1 μg of each probe were mixed with
a 10-fold excess of human Cot-1 DNA. In situ hybridiza-
tion was performed for 48 h, followed by three 5-min
stringency washes in 0.1 × SSC (60°C). The biotin-tagged
H3K27me3 epitopes were detected by means of Avidin-
Alexa488, the CH255-39M12 FISH probe sequentially
with mouse anti-digoxigenin Cy5 and goat anti-mouse
Cy5 antibodies. The 3D-fixed nuclei were counterstained
for 5 min with 2 μg/ml DAPI.
Laser scanning confocal microscopy and image processing
A Leica TCS SP5 laser scanning confocal microscope
(Leica Microsystems, Wetzlar, Germany) with beam split-
ters tuned for DAPI, Alexa 488, TAMRA, TexasRed and
Cy5 was used to scan the nuclei, with an axial distance of
200 nm between consecutive light optical sections yield-
ing separate stacks of 8-bit grayscale images for each fluor-
ochrome channel (pixel size 80 to 120 nm). The confocal
image stacks were processed using ImageJ software [43].
3C Assay
The 3C assay was performed as previously described
[34,35] with minor adaptations. A total of 5 × 107 cells
were resuspended in 2 ml of 4°C cold cell lysis buffer (10
mM Tris, pH 8.0, 10 mM NaCl, 0.2% NP40 and protease
inhibitors), and incubated for 1 h at 4°C, and the nuclei
(1 × 107) were crosslinked in a buffer containing formal-
deyde 1% in 10 mM Tris-Cl, pH 7.9, 10 mM MgCl2, 50
mM NaCl and 1 mM dithiothreitol. The reaction was
quenched by the addition of 0.125 M glycine. The
crosslinked nuclei were resuspended in 500 μl of restric-
tion enzyme buffer and, after the addition of 0.1%
sodium dodecyl sulfate (SDS), incubated at 37°C for 1 h.
Digestion was performed using 800 U of PvuII at 37°C
overnight. The reaction was diluted to a final concentra-
tion of 2.5 ng/μl in a ligation reaction buffer, and 4,000 U
of T4 DNA ligase (NEB, Celbio, Milan, Italy) were added.
The ligations were incubated at 4°C for 8 h. The samples
were treated with proteinase K and incubated overnight at
65°C to reverse the formaldehyde crosslinks. The control
templates were two BACs spanning the FRG1 region and
the D4Z4 array (RP1-226K22 and a D4Z4-containing BAC
isolated from a genomic library screening) (B. Bodega,
unpublished results). Equimolar amounts of the BACs
were mixed and digested with PvuII, which was followed
by ligation in 20 μl. The ligation was controlled as previ-
ously described [34]. The subsequent experiments made
use of an amount of DNA that would amplify within the
linear range. As a standard, the 5' side of each PvuII frag-
ment was used to design the primers, the sequences of
which are available upon request. The PCR products were
quantified using the Typhoon 9200 Image Quant pro-
gram (GE Healthcare, Milan, Italy). A more detailed pro-
tocol is given in Additional file 5.
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Myogenic differentiation properties of myoblasts derived from healthy 
donors and facioscapulohumeral muscular dystrophy (FSHD) 
patients. (a) Human muscle cells utilized in this study: for each line spec-
imen, sex and age at biopsies is indicated; for FSHD patients, D4Z4 con-
traction is reported. The index of fusion was calculated at days 4 and 8 of 
myogenic differentiation and reported. Human myoblast differentiation 
was monitored at 2, 4 and 8 days by (b) immunostaining for sarcomeric 
myosin (green) and MyoD (red) (nuclei are in blue as visualized by 4',6-
diamidino-2-phenylindole (DAPI)), and (c) by reverse transcription 
polymerase chain reaction (RT-PCR) analysis of myosin, MyoD, and 
myogenin muscle-specific markers. 18S rRNA was used as control. (d) 
Expression of sarcomeric myosin was monitored at days 0, 1, 4, and 8 of 
myogenic differentiation by quantitative (q)RT-PCR relative to glyceral-
dehyde 3-phosphate dehydrogenase (GAPDH) expression for all cell lines 
utilized.
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Additional file 2
Distribution on human chromosomes of sequences amplified in chro-
matin immunoprecipitation (ChIP) and methylated DNA immuno-
precipitation (MeDIP) experiments. The table shows the results obtained 
from a polymerase chain reaction (PCR) screening performed to test the 
chromosome specificity of the regions analyzed in the ChIP and MeDIP 
assays; the panel of human somatic cell hybrids were supplied by M. Roc-
chi (see main text). PCR primer pairs were derived from human chromo-
some 4 databank sequences [44], and are reported in Additional file 3.




Primer pairs utilized in this study for chromatin immunoprecipitation 
(ChIP), methylated DNA immunoprecipitation (MeDIP) and reverse 
transcription polymerase chain reaction (RT-PCR) applications. All 
the primer pairs utilized for sequencing and PCR-based analyses are listed 
in the table. For each primer, identification, 5' to 3' sequence and their 
application are reported.




Facioscapulohumeral muscular dystrophy-related gene 1 (FRG1) pro-
moter and D4Z4 units undergo to the same chromatin remodeling events 
during myoblasts differentiation. (a)(i) A simplified scheme of the FRG1 
promoter showing the position of one CarG box responsive element (sequence 
in red) and two E-boxes (sequences in green) in respect to the ATG and tran-
scription start site (+1). Arrowheads indicate primer position for FRG1 A and 
B polymerase chain reaction (PCR) experiments (see Additional file 3 for 
primer sequences). (ii) Chromatin immunoprecipitation (ChIP) experiments 
were carried out on myoblasts and myotubes with antibodies anti-H3K27me3 
(K27), anti-Ezh2 and anti-YY1. Input DNA (+) represents total chromatin, 
while the preimmune chromatin represents the immunoprecipitate obtained 
with a rabbit IgG. (iii) DNA methylation analysis by methylated DNA 
immunoprecipitation (MeDIP) assay on FRG1 A and FRG1 B regions of 
human myoblasts with antibody anti-5-methyl cytidine. Input DNA repre-
sents the supernatant from each genomic DNA. (b)(i) A simplified scheme of 
the D4Z4 unit showing the position of two CarG box responsive elements 
(sequences in red). Arrowheads indicate primer position for Lsau, D4Z4 
binding element (DBE)1 and DBE2 subregions (see Additional file 3 for 
primers); (ii) DNA methylation analysis by MeDIP assay on DBE1 and Lsau 
D4Z4 subregions of human myoblasts with antibody anti-5-methyl cytidine. 
Input DNA represents the supernatant from each genomic DNA. (iii) DNA 
methylation analysis by MeDIP assay of D4Z4 repeats; MeDIP experiments 
were performed with antibody anti-5-methyl cytidine on somatic cell hybrids 
containing as single human representatives chromosome 4 (4), chromosome 
10 (10), chromosome 15 (15) and chromosome 22 (22); the input DNA 
was an aliquot of the supernatant from each centrifuged genomic DNA. All 
DNA regions were PCR amplified on input and immunoprecipitated samples.




Chromosome conformation capture (3C) detailed protocol for human 
myoblasts and myotubes. The detailed chromosome conformation cap-
ture procedure applied on human myoblasts and myotubes is reported. The 
primers utilized in this experiment are also listed.




Example of chromosome conformation capture (3C) analysis per-
formed on myoblasts with D1 bait on D4Z4 unit. (a) Amplification 
bands on 3C artificial control (bacterial artificial chromosomes (BACs) of 
4q locus digested and ligated) and on 3C experiment performed on 
human myoblasts using D1 as bait and F series as prays. (b) Amplifica-
tions of F7-D1 and F18-D1 interactions on BACs, myoblasts and myo-
tubes from three different experiments; on the right, amplification of 
facioscapulohumeral muscular dystrophy-related gene 1 (FRG1) promoter 
(with primers FRG1A) represents a loading control of the amount of 3C 
template used for the polymerase chain reaction (PCR) analysis on BACs, 
myoblasts and myotubes. (c) Quantification of the F7-D1 and F18-D1 
interactions showed in (b); band intensities were measured using a 
Typhoon 9200 phosphoscanner and Image Quant analysis software; PCR 
intensities were first normalized on the corresponding the loading control, 
and expressed as fold factor of the BAC PCR amplification; standard devi-
ation of the mean is indicated. A two-tailed t test was applied for statistical 
analysis. Asterisks indicate the differences that are statistically relevant; 
F7-D1 myoblasts/F7-D1 myotubes, P = 0.024.




Facioscapulohumeral muscular dystrophy-related gene 1 (FRG1) pro-
moter and D4Z4 array physically interact within chromosome 4. (a) 
Diagram of the genomic region analyzed in chromosome conformation 
capture (3C) experiments; PvuII restriction sites are indicated (thin ver-
tical lines); arrowheads indicate primer positions, F series in FRG1 gene 
and D series in D4Z4 repeats. Red rectangles indicate the location of 
CarG boxes. (b) Crosslinking frequencies between the fixed PvuII frag-
ment D1 (D4Z4 repeats) and the rest of the facioscapulohumeral muscu-
lar dystrophy (FSHD) locus in monochromosomal somatic cell hybrid 
retaining the human chromosome 4. All data points were generated from 
an average of three independent experiments. The standard error of the 
mean is indicated. One-way analysis of variance (ANOVA) was applied 
for statistical analysis; a = 0.05, P = 7.36*10-5. Primers are listed in 
Additional file 5, in the detailed 3C protocol section. (c) Crosslinking fre-
quencies between the fixed PvuII fragment C1 (DUX4c region) and the 
rest of the FSHD locus in myoblasts (black) and myotubes (pink). All data 
points were generated from an average of three independent experiments 
performed in control myoblasts cell lines. The standard error of the mean 
is indicated. One-way ANOVA was applied for statistical analysis; myob-
lasts: a = 0.05, P = 0.002; myotubes: a = 0.05, P = 0.061.
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